secwatch.observer — SEC 8-K summary
======================================

Issuer:     Baudax Bio, Inc. (—)
CIK:        0001780097
Form:       8-K/A
Filed at:   2023-04-04T23:59:59+00:00
Accession:  0001193125-23-090855
Event type: m_and_a
Sentiment:  negative
Materiality: 0.90
Item codes: 1.01, 1.02, 2.01, 2.03, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Baudax Bio transfers ANJESO assets to Alkermes, terminates related agreements, amends credit facility
--------------------------------------------------------------------------------

- Transferred patents, trademarks, equipment, data, and ANJESO NDA to Alkermes; no further payments due under terminated ANJESO agreements.
- Amended credit agreement: lenders consented to asset sale, released liens on transferred assets, reduced minimum liquidity covenant to $2.5M.
- Issued warrants to MAM Eagle Lender for 785,026 shares at $1.8951/share, exercisable for 10 years; registration rights granted.
- Company will withdraw ANJESO NDA and transfer to Alkermes if requested; acquired regulatory approvals included in transfer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1780097/000119312523090855/0001193125-23-090855-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1780097/000119312523090855/d460062d8ka.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-090855

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer